Biopharmaceutical News and Research

RSS

Novel method can detect contaminants in T-cell cultures within 24 hours

Researchers from Critical Analytics for Manufacturing Personalized-Medicine (CAMP) Interdisciplinary Research Group (IRG) at Singapore-MIT Alliance for Research and Technology (SMART), MIT's research enterprise in Singapore, in collaboration with Singapore Centre for Environmental Life Sciences Engineering (SCELSE) and Massachusetts Institute of Technology (MIT), have developed a novel method capable of identifying contaminants in T-cell cultures within 24 hours.

27 Nov 2023

Almirall and Absci partner to develop AI-designed therapeutics for dermatological diseases

Almirall S.A., a global biopharmaceutical company focused on medical dermatology, and Absci Corporation, a generative AI drug creation company, today announced a drug discovery partnership aimed to develop and commercialize AI-designed therapeutics to fight chronic and debilitating dermatological diseases. The partnership combines Absci’s Integrated Drug Creation™ platform with Almirall’s dermatological expertise with the goal of delivering life-changing medicines to patients, marking another step forward in AI drug creation.

20 Nov 2023

Tackling Antimicrobial Resistance Together: A Conversation with Dr. Beverley Isherwood

An interview with Dr Beverley Isherwood.

16 Nov 2023

ATCC announces award from national institute of allergy and infectious diseases to support its preclinical services for biopharmaceutical product development

ATCC today announced that it has been awarded an Indefinite Delivery/Indefinite Quantity (IDIQ) contract.

From ATCC 13 Nov 2023

Data, Design, and Discovery: Andrew Buchanan's Impact on Biologics Innovation

Andrew Buchanan on the Future of Biologics and AI

10 Nov 2023

MD Anderson and Jazz Pharmaceuticals collaborate to investigate the potential of zanidatamab in HER2-expressing cancers

The University of Texas MD Anderson Cancer Center and Jazz Pharmaceuticals plc today announced a five-year strategic research collaboration agreement to evaluate zanidatamab, Jazz's investigational HER2-targeted bispecific antibody, in multiple HER2-expressing cancers.

7 Nov 2023

Lario Therapeutics receives “Company Making a Difference Award” from CDLK5 Forum, recognising its unique approach to precision medicine for genetic epilepsies

“CDLK5 Forum Award for Excellence - Company Making a Difference 2023 Pre-clinical” presented by the Loulou Foundation at the CDKL5 Forum, 6th-7th November in London

7 Nov 2023

UTHSC's drug candidate for advanced prostate cancer goes to first clinical trial

A drug candidate developed by researchers at the University of Tennessee Health Science Center for advanced metastatic castration-resistant prostate cancer is now in its first clinical trial.

6 Nov 2023

The New Picus® 2 sets a new standard for connected electronic pipettes

Sartorius launches new electronic pipette Picus 2.

From Sartorius 16 Oct 2023

Scientists identify nearly a dozen genes responsible for coronary artery calcification

An international team of scientists has identified nearly a dozen genes that contribute to calcium buildup in our coronary arteries that can lead to life-threatening coronary artery disease, a condition responsible for up to one in four deaths in the United States.

11 Oct 2023

Study provides evidence for combination therapy as first-line treatment for relapsed ITP

Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences &Peking Union Medical College, conducted a multicenter comprehensive retrospective analysis to assess the effectiveness and safety of primary single-agent and combination therapies in treating adult patients with relapsed immune thrombocytopenia (ITP).

9 Oct 2023

Mogrify extends Series A financing to $46 million USD

Mogrify Limited (Mogrify®), a biopharmaceutical company transforming the lives of patients through a novel class of in vivo reprogramming therapies, announced today an additional $10 million USD closing of its Series A financing.

From Mogrify 2 Oct 2023

PhenomeX announces the release of SpotLight™ Human Lambda reagent for the Beacon® platform to accelerate cell line development workflows

PhenomeX Inc., a functional cell biology company, is pleased to announce that GSK will present data on the SpotLight™ Human Lambda reagent for the Beacon® platform at the 16th annual Conference on Protein Expression in Animal Cells, which is being held in Sitges, Spain from September 24-28, 2023.

From Bruker Cellular Analysis 25 Sep 2023

Innovations in baculovirus–insect cell expression systems

The baculovirus–insect cell expression system—insect cells used in conjunction with the baculovirus expression vector system (BEVS)— remains a crucial technology for manufacturing large and complex proteins. This eukaryotic expression system offers inherent safety, ease of scale-up, flexible product design, and versatility for a broad range of proteins.

From Sino Biological Inc. 20 Sep 2023

Nuvectis launches Phase 1a dose escalation clinical trial of new cancer drug

Clinical trials have begun for a drug candidate for hard-to-treat cancers, discovered at the University of Edinburgh and licensed by US biopharmaceutical company Nuvectis Pharma, Inc.

15 Sep 2023

Organon Bolsters Research & Development Expertise with Two Leadership Appointments

Organon (NYSE: OGN), a global healthcare company with a focus on women’s health, today announced the appointment of Juan Camilo Arjona Ferreira, M.D., as Chief Medical Officer (CMO) and Charlotte Owens, M.D., as Head of Medical Affairs and Outcomes Research.

7 Sep 2023

Optibrium acquires BioPharmics LLC, expanding its 3D drug design and visualisation offering

Optibrium, a leading developer of software and AI solutions for drug discovery, today announced the acquisition of BioPharmics LLC.

From Optibrium Ltd. 31 Aug 2023

Drexel University receives grants to support cell and gene therapy education

Drexel University's School of Biomedical Engineering, Science and Health Systems, in collaboration with Drexel's College of Medicine, has received grants from the pharmaceutical company Bristol Myers Squibb, to support the education and training of diverse and talented students looking to pursue careers in cell and gene therapy.

25 Aug 2023

Speech Accessibility Project needs more participants with Parkinson's

The Speech Accessibility Project is almost halfway through its first phase of gathering voice recordings from people with Parkinson's.

24 Aug 2023

New treatment approach shows promise in reversing hormone resistance in breast cancer

A collaborative study between LSU Health New Orleans School of Medicine, the University of Rochester and Cellestia Biotech AG, a biopharmaceutical company headquartered in Basel, Switzerland, provides compelling evidence that combining an investigational oral drug with standard-of-care medications reverts hormone resistance and increases Rx effectiveness in experimental models of estrogen-receptor positive (ER+) and triple-negative breast cancers (TNBC), respectively.

9 Aug 2023